Program
desethyloxybutynin
Also written as “NRX-101” and “NRX-101 Oral Capsule”.
Its studies are mostly in Bipolar Disorder · Depressive Disorder, Treatment-Resistant, led by NeuroRx.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NeuroRx | 42 open or running | phase 3since Nov 2, 2017 | Nov 22, 2016 | Dec 31, 2027phase 3 · NCT07227103 |
Also a collaborator on its studies: target-health-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 22, 2016First study: phase 2 study in Bipolar DisorderFirst studyNCT02974010 · 22 enrolled · United States
- Nov 2, 2017Phase 3 study in Bipolar DisorderNCT03396068 · 72 enrolled · United States
- Jan 4, 2018Phase 3 study in Bipolar DisorderNCT03395392 · 74 enrolled · United States
- Nov 9, 2025Phase 3 study in Depressive Disorder, Treatment-ResistantNCT07227103 · 240 planned · United States
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Depressive Disorder, Treatment-ResistantNCT07227103
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07227103Depressive Disorder, Treatment-Resistant · United States | 3 | Recruiting | Dec 31, 2027 | 240 |
| NCT03395392Bipolar Disorder · United States | 3 | Completed | Feb 28, 2024 | 74 |
| NCT03396068Bipolar Disorder · United States | 3 | Active, not recruiting | Dec 31, 2024 | 72 |
| NCT02974010Bipolar Disorder · United States | 2 | Completed | Aug 31, 2018 | 22 |
How it is read
Names in the registry
- “NRX-101”, 3 entries
- “NRX-101 Oral Capsule”, 1 entry
Conditions, from the studies’ own filings
- Bipolar Disorder, 3 studies
- Depressive Disorder, Treatment-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.